File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.amjmed.2012.01.024
- Scopus: eid_2-s2.0-84862661539
- PMID: 22608789
- WOS: WOS:000305752700015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Recent progress in the treatment of proliferative lupus nephritis
Title | Recent progress in the treatment of proliferative lupus nephritis |
---|---|
Authors | |
Keywords | Azathioprine Cyclophosphamide Lupus Nephritis Mycophenolate Mofetil |
Issue Date | 2012 |
Publisher | Excerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amj |
Citation | American Journal Of Medicine, 2012, v. 125 n. 7, p. 642-648 How to Cite? |
Abstract | The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This review focuses on the new treatments that have emerged over the past 2 decades. The data and methodology of important clinical trials are discussed to highlight the important findings and their limitations. The role of mycophenolate mofetil as induction or maintenance immunosuppressive treatment is discussed in detail. Racial variations in prognosis and treatment response are evident. With increasing treatment options and better appreciation of patient characteristics that impact on response and tolerance, the management of lupus nephritis has become more individualized. The choice and the dosing regimen of immunosuppressive agents should take into account factors such as race, type of lupus nephritis, disease severity, renal reserve, and prior disease course, to aim for an optimal balance of benefit and risk. © 2012 Elsevier Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/163500 |
ISSN | 2023 Impact Factor: 5.1 2023 SCImago Journal Rankings: 1.063 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, TM | en_US |
dc.date.accessioned | 2012-09-05T05:32:21Z | - |
dc.date.available | 2012-09-05T05:32:21Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | American Journal Of Medicine, 2012, v. 125 n. 7, p. 642-648 | en_US |
dc.identifier.issn | 0002-9343 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163500 | - |
dc.description.abstract | The recent decades have witnessed significant progress in the treatment of lupus nephritis. Existing immunosuppressive regimens have been refined to enhance efficacy and reduce adverse effects, resulting in improvements in renal and patient survival and patients' quality of life. This review focuses on the new treatments that have emerged over the past 2 decades. The data and methodology of important clinical trials are discussed to highlight the important findings and their limitations. The role of mycophenolate mofetil as induction or maintenance immunosuppressive treatment is discussed in detail. Racial variations in prognosis and treatment response are evident. With increasing treatment options and better appreciation of patient characteristics that impact on response and tolerance, the management of lupus nephritis has become more individualized. The choice and the dosing regimen of immunosuppressive agents should take into account factors such as race, type of lupus nephritis, disease severity, renal reserve, and prior disease course, to aim for an optimal balance of benefit and risk. © 2012 Elsevier Inc. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Excerpta Medica, Inc. The Journal's web site is located at http://www.elsevier.com/locate/amj | en_US |
dc.relation.ispartof | American Journal of Medicine | en_US |
dc.subject | Azathioprine | en_US |
dc.subject | Cyclophosphamide | en_US |
dc.subject | Lupus Nephritis | en_US |
dc.subject | Mycophenolate Mofetil | en_US |
dc.title | Recent progress in the treatment of proliferative lupus nephritis | en_US |
dc.type | Article | en_US |
dc.identifier.email | Chan, TM:dtmchan@hku.hk | en_US |
dc.identifier.authority | Chan, TM=rp00394 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.amjmed.2012.01.024 | en_US |
dc.identifier.pmid | 22608789 | - |
dc.identifier.scopus | eid_2-s2.0-84862661539 | en_US |
dc.identifier.hkuros | 239873 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84862661539&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 125 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.spage | 642 | en_US |
dc.identifier.epage | 648 | en_US |
dc.identifier.isi | WOS:000305752700015 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Chan, TM=7402687700 | en_US |
dc.identifier.issnl | 0002-9343 | - |